To assess the effectiveness of topical tapinarof to topical betamethasone in patients with mild to moderate plaque psoriasis presenting to tertiary care hospital in Islamabad

Inclusion Criteria:

• Age 18 years-65 years
• Clinically diagnosed plaque psoriasis involving body surface area ( BSA) of 2-20% (mild to moderate severity)
• Disease duration of at least 6 months
• Willing and able to provide written informed consent
• Not currently using any other topical and systematic psoriasis therapy, or willing to undergo a washout period (2 weeks for topical therapies)

Exclusion Criteria:

• Severe psoriasis (BSA >20% or requiring systemic therapy)
• Pregnant and lactating mothers
• Known hypersensitivity to Tapinarof or any of its excipients
• Concurrent dermatological conditions that may interfere with assessment e.g fungal infections,atopic dermatitis
• Use of systemic immunosuppressants (methotrexate, cyclosporine, biologics ) or phototherapy within 4 weeks before enrollment
• History of malignancy or current active infection
• Known hypersensitivity to betamethasone or Tapinarof
• Use of powerful topical corticosteroids within two weeks previously